Article Tools

Intercell AG provides update on IXIARO®/JESPECT® sales growth and expected full year financial performance

Published: October 16, 2012; 07:32 · (Vindobona)

Intercell AG provides update on IXIARO®/JESPECT® sales growth and expected full year financial performance

Intercell AG provides update on IXIARO®/JESPECT® sales growth and expected full year financial performance / Picture: © Vindobona.org adhoc disclosure transmitted by euro adhoc with the aim of a Europewide distribution. The issuer is solely responsible for the content of this announcement.

16.10.2012

» Preliminary, unaudited third quarter close shows approximately EUR 18m
IXIARO®/JESPECT® sales for the nine months ended September 30th 2012 -
representing significant growth compared to EUR 15.5m sales in the same period
of 2011

» However, previous sales growth expectations had been higher and full year
sales and net loss expectations are therefore lowered by 10% to 20%

Vienna, October 16, 2012 - Intercell AG (VSE: ICLL) today announced an
adjustment of its product sales expectations for IXIARO®/JESPECT®, a vaccine to
prevent Japanese Encephalitis, and expected full year net loss ahead of its Q3
2012 financial results announcement, scheduled for November 7th, 2012.

Following an analysis of recent vaccine adoption trends and the expected order
intake for the rest of the year, Intercell now expects 2012 IXIARO®/JESPECT®
sales growth of EUR 5m to 7m, resulting in expected product sales between EUR
26.5m and 28.5m for the full year 2012 (2011: EUR 21.6m). The company also
updated the range of its expected full year net loss to EUR 20m to 24m. For the
nine months ended September 30th, 2012, Intercell expects to report a net loss
of approximately EUR 14.5m to 15m.

Based on the expected orders and demand, and subject to timely product release
to secure supply of the vaccine, the revised full year product sales expectation
assumes strong Q4 sales of EUR 8.5m to 10.5m (Q4 2011: EUR 6.1m) underscoring
the unlocked potential of this vaccine.

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime

stockmarkets: official market: Wien
language: English

Digital press kit: http://www.ots.at/pressemappe/116/aom

***ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS
RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER***

OTE0001 2012-10-16/07:32

(C) Copyright APA-OTS Originaltext-Service GmbH and the respective issuer.

Fast News Search
Read More
ISIN
AT0000612601